Skip to content
Peptigraph home

CJC-1295 Half-Life: How Long It Stays in Your System

How long CJC-1295 stays in the body, how that shapes dosing frequency, and what is known about drug testing.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGHRH analogUpdated
Half-life
Not found
No published half-life found (PubMed search, 2 Oct 2026)
Dosing interval
Varies by study
as used in studies
WADA
Prohibited (S2.2.4)
In and out of competition
Detection window
2 findings
from anti-doping studies, below

CJC-1295 half-life

Half-life: no published half-life found (PubMed search, 2 Oct 2026). A half-life depends on the route (under the skin, into a vein, by mouth or nasal spray), so we report it per route with the study it came from.

Other pharmacokinetic findings (these are not half-life values):

CJC-1295: other pharmacokinetic findings
RouteHalf-lifeMeasured inSource
subcutaneous5.8-8.1 d (estimated half-life)PeopleThe Journal of clinical endocrinology and metabolism 2006, PMID 16352683
injection (route not stated)8 d (stated as half-life in the abstract background)PeopleThe Journal of clinical endocrinology and metabolism 2006, PMID 17018654
subcutaneouspresent in plasma beyond 72 h (no half-life value given)Animal · ratEndocrinology 2005, PMID 15817669

What half-life means

Half-life is the time it takes for the amount of a drug in the blood to fall by half. After one half-life, about 50% is left; after two, about 25%; after four to five, only a few percent remain.

  • A long half-life lets a drug be dosed less often, for example once a week.
  • A short half-life means levels rise and fall quickly, which is why some peptides are given daily or more often.
  • Effects can outlast blood levels, so half-life alone does not tell you how long a drug works.

What it means for dosing frequency

Dosing intervals used in published studies of CJC-1295:

Changing the interval changes how much drug builds up between doses, so it is not a free choice.

Drug tests and sport

Prohibited by WADA (S2.2.4)

CJC-1295 is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times.

Detection findings from anti-doping analytical studies:

  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations. · PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples. · PMID 34665524

Tested athletes should treat it as prohibited (s2.2.4) at all times.

Common questions

How long does CJC-1295 stay in your system?

We found no published half-life for CJC-1295 (PubMed search, 2 Oct 2026). As a rule, most of a dose is cleared after about four to five half-lives.

What is the half-life of CJC-1295?

No published half-life was found in our PubMed search, 2 Oct 2026. We add one with its source and route if a study reports it.

Is CJC-1295 on the WADA prohibited list?

Yes. Prohibited by WADA (S2.2.4).

More on CJC-1295

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  3. 3Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  4. 4Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  5. 5Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
  6. 6Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.Endocrinology · 2005PMID 15817669Accessed 2 Oct 2026
  7. 7Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
  8. 8PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.